Filana Therapeutics, Inc. (FLNA) Stock

NASDAQ: FLNAHealthcare company in the biotechnology industry, based in Austin, TX.

Filana Therapeutics stock price chart

FLNA interactive chart →

FLNA stock quote & key statistics

Filana Therapeutics earnings per share

Income →
Earnings per share

Filana Therapeutics revenue & net income

Income →
RevenueNet income

Filana Therapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$91.0M-$1.88
FY2024$0-$24.3M-$2.86
FY2023$0-$97.2M-$2.32
FY2022$0-$76.2M-$1.90

Fiscal year ending December 31. Source: company filings via EODHD.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Filana Therapeutics stock FAQ

What is the Filana Therapeutics stock ticker symbol?

Filana Therapeutics, Inc. trades on the NASDAQ under the ticker symbol FLNA.

What sector and industry is Filana Therapeutics in?

Filana Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Filana Therapeutics have?

Filana Therapeutics, Inc. has about 17 full-time employees.

What were Filana Therapeutics's revenue and earnings last fiscal year?

Filana Therapeutics reported revenue of $0 and net income of -$91.0M in fiscal 2025, with earnings per share of -$1.88.

When did Filana Therapeutics go public?

Filana Therapeutics stock began trading on July 14, 2000.

Biotechnology stocks

All Healthcare stocks →